Characterization of circulating CD8+T cells expressing skin homing and cytotoxic molecules in active non-segmental vitiligo

European Journal of Dermatology

Volumn 23, Issue 3, 2013, Pages 331-338

  Zhang, Bao Xiang ^a,c   Lin, Mao ^a   Qi, Xiao Yi ^a   Zhang, Ron Xin ^a   Wei, Zhen Dong ^a   Zhu, Jie ^a   Man, Mao Qiang ^b   Tu, Cai Xia ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION   (United States)

^c WEIFANG MEDICAL UNIVERSITY   (China)

Author keywords

CD8+T cell; Cutaneous lymphocyte associated antigen; Granzyme B; Perforin; Vitiligo

Indexed keywords

CD3 ANTIGEN; CHEMOKINE RECEPTOR CCR10; CHEMOKINE RECEPTOR CCR4; CUTANEOUS LYMPHOCYTE ASSOCIATED ANTIGEN; FAS LIGAND; GRANZYME B; PERFORIN; GRANZYME; GZMB PROTEIN, HUMAN; HOMING RECEPTOR;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CELL HOMING; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; LYMPHOCYTE MIGRATION; PROTEIN EXPRESSION; SCORING SYSTEM; SKIN PIGMENTATION; VITILIGO; BIOSYNTHESIS; BLOOD; FEMALE; IMMUNOLOGY; MALE; METABOLISM;

ADULT; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRANZYMES; HUMANS; MALE; PERFORIN; RECEPTORS, LYMPHOCYTE HOMING; VITILIGO;

EID: 84880601236     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2013.2011     Document Type: Article

References (33)

1. Huggins RH, Schwartz RA, Janniger CK. Vitiligo. Acta Dermatovenerol Alp Panonica Adriat 2005; 14: 137-42.
2. Rezaei N, Gavalas NG, Weetman AP, Kemp EH. Autoimmunity as an aetiological factor in vitiligo. J Eur Acad Dermatol Venereol 2007; 21: 865-76.
3. Gregg RK, Nichols L, Chen Y, Lu B, Engelhard VH. Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinasespecific TCR transgenic mice. J Immunol 2010; 184: 1909-17.
4. Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A Mouse Model of Vitiligo with Focused Epidermal Depigmentation Requires IFN-gamma for Autoreactive CD8(+) T-Cell Accumulation in the Skin. J Invest Dermatol 2012; 132: 1869-76.
5. van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129: 2220-32.
6. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999; 401: 708-12.
7. Ogg GS, Rod DP, Romero P, Chen JL, Cerundolo V. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188: 1203-8.
8. van den WR, Wankowicz-Kalinska A, Le PC, Tigges B, Westerhof W, Das P. Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA+ T cells at the perilesional site. Lab Invest 2000; 80: 1299-309.
9. Santamaria-Babi LF. CLA(+) T cells in cutaneous diseases. Eur J Dermatol 2004; 14: 13-8.
10. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cellattracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001; 194: 1541-7.
11. Wu XS, Lonsdorf AS, Hwang ST. Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. J Invest Dermatol 2009; 129: 1115-9.
12. Oyarbide-Valencia K, van den Boorn JG, Denman CJ, et al. Therapeutic implications of autoimmune vitiligo T cells. Autoimmun Rev 2006; 5: 486-542.
13. Kim NH, Jeon S, Lee HJ, Lee AY. Impaired PI3K/Akt activationmediated NF-kappaB inactivation under elevated TNF-alpha is more vulnerable to apoptosis in vitiliginous keratinocytes. J Invest Dermatol 2007; 127: 2612-7.
14. Tu CX, Jin WW, Lin M, Wang ZH, Man MQ. Levels of TGFbeta(1) in serum and culture supernatants of CD4(+)CD25(+) T cells from patients with non-segmental vitiligo. Arch Dermatol Res 2011; 303: 685-9.
15. Alghamdi KM, Kumar A, Taïeb A, Ezzedine K. Assessment methods for the evaluation of vitiligo. J Eur Acad Dermatol Venereol 2012; 26: 1463-71.
16. Yano S, Nakamura K, Okochi H, et al. Analysis of the expression of cutaneous lymphocyte-associated antigen on the peripheral blood and cutaneous lymphocytes of alopecia areata patients. Acta Derm. Venereol 2002; 82: 82-5.
17. Sigmundsdottir H, Gudjonsson JE, Jonsdottir I, et al. The frequency of CLA+ CD8+ T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin. Exp. Immunol 2001; 126: 365-9.
18. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol 1999; 163: 4335-41.
19. Chavez-Galan L, renas-Del Angel MC, Zenteno E, Chavez R, Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol 2009; 6: 15-25.
20. Lili Y, Yi W, Ji Y, et al. Global activation of CD8+ cytotoxic T lymphocytes correlates with an impairment in regulatory T cells in patients with generalized vitiligo. PloS One 2012; 7: e37513.
21. Vugmeyster Y, Kikuchi T, Lowes MA, et al. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin. Clin Immunol 2004; 113: 38-46.
22. Harper EG, Simpson EL, Takiguchi RH, et al. Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. J Invest Dermatol 2008; 128: 1173-81.
23. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004; 4: 211-22.
24. Pont-Giralt M, Giménez-Arnau AM, Pujol RM, Santamaria-Babi LF. Circulating CLA(+) T cells from acute and chronic psoriasis patients manifest a different activation state and correlation with disease severity and extension. J Invest Dermatol 2006; 126: 227-8.
25. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999; 400: 776-80.
26. Homey B, Wang W, Soto H, et al. Cutting edge: the orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J Immunol 2000; 164: 3465-70.
27. Campbell JJ, O'Connell DJ, Wurbel MA, Cutting Edge: MA. Chemokine receptor CCR4 is necessary for antigen-driven cutaneous accumulation of CD4 T cells under physiological conditions. J Immunol 2007; 178: 3358-62.
28. Fujimoto S, Uratsuji H, Saeki H, et al. CCR4 and CCR10 are expressed on epidermal keratinocytes and are involved in cutaneous immune reaction. Cytokine 2008; 44: 172-8.
29. Wenzel J, Gutgemann I, Distelmaier M, et al. The role of cytotoxic skin-homing CD8+ lymphocytes in cutaneous cytotoxic T-cell lymphoma and pityriasis lichenoides. J Am Acad Dermatol 2005; 53: 422-7.
30. Teraki Y, Miyake A, Takebayashi R, Shiohara T. Homing receptor and chemokine receptor on intraepidermal T cells in psoriasis vulgaris. Clin Exp Dermatol 2004; 29: 658-63.
31. Homey B, Alenius H, Muller A, et al. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat Med 2002; 8: 157-65.
32. Notohamiprodjo M, Segerer S, Huss R, et al. CCR10 is expressed in cutaneous T-cell lymphoma. Int J Cancer 2005; 115: 641-7.
33. Hudak S, Hagen M, Liu Y, et al. Immune surveillance and effector functions of CCR10(+) skin homing T cells. J Immunol 2002; 169: 1189-96.